Morgan Stanley Maintains Overweight Rating on Abbott Laboratories

A report from Morgan Stanley reiterates its Overweight rating on Abbott Laboratories (NYSE: ABT).

The report states, “We believe there is significant runway remaining for Abbott Vascular in terms of market share capture, particularly in peripheral vascular, which includes balloons, stents and wires. We see this approach as consistent with our expectations in terms of business strategy.”

ABT closed Friday at $54.53.